Quantitative and qualitative effects of rosuvastatin on LDL-cholesterol: What is the clinical significance?

International Journal of Clinical Practice

Volumn 63, Issue 3, 2009, Pages 478-485

  Rizzo, M ^a   Berneis, K ^b   Spinas, G A ^b   Rini, G B ^a   Kapur, N K ^c  

^a UNIVERSITY OF PALERMO   (Italy)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c TUFTS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; ATORVASTATIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL ASSESSMENT; CLINICAL FEATURE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DENSITY; DIABETES MELLITUS; DISEASE CONTROL; DRUG DOSE TITRATION; DRUG EFFECT; DRUG SAFETY; DYSLIPIDEMIA; HEART DISEASE; HEMODIALYSIS; HUMAN; INTERVENTION STUDY; INTROSPECTION; LEADERSHIP; LONG TERM CARE; MEDLINE; POPULATION; PRIMARY PREVENTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVIEW; SAFETY; SOUTH ASIA; STATISTICAL SIGNIFICANCE; TAXONOMY; TREATMENT DURATION;

AGED; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; CLINICAL TRIALS AS TOPIC; FLUOROBENZENES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; PRIMARY PREVENTION; PYRIMIDINES; SULFONAMIDES; TREATMENT OUTCOME;

EID: 59349087902     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2008.01979.x     Document Type: Review

References (69)

1. National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002 106 : 3143 421.
2. Wierzbicki AS. Quality as well as quantity? Beyond low-density lipoprotein-cholesterol - the role of particle size. Int J Clin Pract 2007 61 : 1780 2.
3. Berneis KK, Krauss RM. Metabolic origins and clinical significance of LDL heterogeneity. J Lipid Res 2002 43 : 1363 79.
4. Griffin BA, Caslake MJ, Yip B, Tait GW, Packard CJ, Shepherd J. Rapid isolation of low density lipoprotein (LDL) subfractions from plasma by density gradient ultracentrifugation. Atherosclerosis 1990 83 : 59 67.
5. Rizzo M, Berneis K. Low-density-lipoproteins size and cardiovascular risk assessment. QJM Int J Med 2006 99 : 1 14.
6. Julius U, Dittrich M, Pietzsch J. Factors influencing the formation of small dense low-density lipoprotein particles in dependence on the presence of the metabolic syndrome and on the degree of glucose intolerance. Int J Clin Pract 2007 61 : 1798 804.
7. St Pierre AC, Cantin B, Dagenais GR et al. Low-density lipoprotein subfractions and the longterm risk of ischemic heart disease in men: 13-year follow-up data from the Quebec Cardiovascular Study. Arterioscler Thromb Vasc Biol 2005 25 : 553 9.
8. Rizzo M, Berneis K. The clinical relevance of low-density-lipoproteins size modulation by statins. Cardiovasc Drug Ther 2006 20 : 205 17.
9. Jones PH, Davidson MH, Stein EA et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol 2003 92 : 152 60.
10. Rizzo M, Rini GB, Berneis K. Effects of statins, fibrates, rosuvastatin and ezetimibe beyond cholesterol: the modulation of LDL size and subclasses in high-risk patients. Adv Ther 2007 24 : 575 82.
11. Bjornheden T, Babyi A, Bondjers G, Wiklund O. Accumulation of lipoprotein fractions and subfractions in the arterial wall, determined in an in vitro perfusion system. Atherosclerosis 1996 123 : 43 56.
12. Galeano NF, Al-Haideri M, Keyserman F, Rumsey SC, Deckelbaum RJ. Small dense low density lipoprotein has increased affinity for LDL receptor-independent cell surface binding sites: a potential mechanism for increased atherogenicity. J Lipid Res 1998 39 : 1263 73.
13. Camejo G, Lopez A, Lopez F, Quinones J. Interaction of low density lipoproteins with arterial proteoglycans. The role of charge and sialic acid content. Atherosclerosis 1985 55 : 93 105.
14. Tribble DL, Rizzo M, Chait A, Lewis DM, Blanche PJ, Krauss RM. Enhanced oxidative susceptibility and reduced antioxidant content of metabolic precursors of small, dense low-density lipoproteins. Am J Med 2001 110 : 103 10.
15. Tribble DL, Holl LG, Wood PD, Krauss RM. Variations in oxidative susceptibility among six low density lipoprotein subfractions of differing density and particle size. Atherosclerosis 1992 93 : 189 99.
16. de Graaf J, Hak-Lemmers HL, Hectors MP, Demacker PN, Hendriks JC, Stalenhoef AF. Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects. Arterioscler Thromb 1991 11 : 298 306.
17. Sacks FM, Campos H. Low-density lipoprotein size and cardiovascular disease: a reappraisal. J Clin Endocr Metab 2003 88 : 4525 32.
18. Lamarche B, Lemieux I, Despres JP. The small, dense LDL phenotype and the risk of coronary heart disease: epidemiology, patho-physiology and therapeutic aspects. Diabetes Metab 1999 25 : 199 211.
19. Lada AT, Rudel LL. Associations of low density lipoprotein particle composition with atherogenicity. Curr Opin Lipidol 2004 15 : 19 24.
20. Cromwell WC, Otvos JD. Low-density lipoprotein particle number and risk for cardiovascular disease. Curr Atheroscler Rep 2004 6 : 381 7.
21. Guerin M, Le Goff W, Lassel TS, Van Tol A, Steiner G, Chapman MJ. Atherogenic role of elevated CE transfer from HDL to VLDL(1) and dense LDL in type 2 diabetes : impact of the degree of triglyceridemia. Arterioscler Thromb Vasc Biol 2001 21 : 282 8.
22. Rizzo M, Taylor JM, Barbagallo CM, Berneis K, Blanche PJ, Krauss RM. Effects on lipoprotein subclasses of combined expression of human hepatic lipase and human apoB in transgenic rabbits. Arterioscler Thromb Vasc Biol 2004 24 : 141 6.
23. El Harchaoui K, van der Steeg WA, Stroes ES et al. Value of low-density lipoprotein particle number and size as predictors of coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study. J Am Coll Cardiol 2007 49 : 547 53.
24. Brewer HB. Benefit-risk assessment of Rosuvastatin 10 to 40 milligrams. Am J Cardiol 2003 92 : 23K 9K.
25. Olsson AG, Istad H, Luurila O et al. Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia. Am Heart J 2002 144 : 1044 51.
26. Schneck DW, Knopp RH, Ballantyne CM et al. Comparative effects of rosuvastatin and atorvastatin across their dose ranges in patients with hypercholesterolemia and without active arterial disease. Am J Cardiol 2003 91 : 33 41.
27. Tuomilehto J, Leiter LA, Kallend D. A review of the efficacy of rosuvastatin in patients with type 2 diabetes. Int J Clin Pract 2004 143 (Suppl. 30 40.
28. Krum H, Tonkin A. The rosuvastatin impact on ventricular remodelling cytokines and neurohormones (UNIVERSE) study [Abstract]. J Am Coll Cardiol 2006 26 : 61A 2A.
29. Raina A, Pickering T, Shimbo D. Statin use in heart failure - a cause for concern? Am Heart J 2006 152 : 39 49.
30. Ferdinand KC, Clark LT, Watson KE et al. Comparison of efficacy and safety of rosuvastatin versus atorvastatin in African-American patients in a six-week trial. Am J Cardiol 2006 97 : 229 35.
31. Llorett R, Haffner S, Ycas J, Stein M et al. for the STARSHIP Study Group. Lipid-lowering results from the first large-scale trial of statin therap in Hispanic-American patients with hypercholesterolemia: STARSHIP [Abstract]. J Am Coll Cardiol 2006 26 : 349A 50A.
32. Deedwania P, Gupta M, Stein M et al. First large randomized trial of a statin therapy in South Asian patients at risk for coronary heart disease: the IRIS trial. Atherosclerosis 2006 206 (Suppl. 161.
33. Brown WV, Bays HE, Hassman DR et al. Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: a randomized, double-blind, 52-week trial. Am Heart J 2002 144 : 1036 43.
34. Ridker PM, Danielson E, Fonseca FAH et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008 359 : 2195 207.
35. Hlatky MA. Expanding the orbit of primary prevention - moving beyond JUPITER. N Engl J Med 2008 359 : 2280 2.
36. Bassler D, Montori VM, Briel M, Glasziou P, Guyatt G. Early stopping of randomized trials for overt efficacy is problematic. J Clin Epidemiol 2008 61 : 241 6.
37. Caslake MJ, Stewart G, Day SP et al. Phenotype-dependent and -independent actions of rosuvastatin on atherogenic lipoprotein subfractions in hyperlipidaemia. Atherosclerosis 2003 171 : 245 53.
38. Kostapanos MS, Milionis HJ, Filippatos TD et al. A 12-week, prospective, open-label analysis of the effect of rosuvastatin on triglyceride-rich lipoprotein metabolism in patients with primary dyslipidemia. Clin Ther 2007 29 : 1403 14.
39. Ai M, Otokozawa S, Asztalos BF et al. Effects of maximal doses of atorvastatin versus rosuvastatin on small dense low-density lipoprotein cholesterol levels. Am J Cardiol 2008 101 : 315 8.
40. Kostapanos MS, Milionis HJ, Lagos KG, Rizos CB, Tselepis AD, Elisaf MS. Baseline triglyceride levels and insulin sensitivity are major determinants of the increase of LDL particle size and buoyancy induced by rosuvastatin treatment in patients with primary hyperlipidemia. Eur J Pharmacol 2008 590 : 327 32.
41. Rizzo M, Berneis K. Small, dense low-density-lipoproteins and the metabolic syndrome. Diabetes Metab Res Rev 2007 23 : 14 20.
42. Hoefner DM, Hodel SD, O'Brien JF et al. Development of a rapid, quantitative method for LDL subfractionation with use of the Quantimetrix Lipoprint LDL System. Clin Chem 2001 47 : 266 74.
43. Ensign W, Hill N, Heward CB. Disparate LDL phenotypic classification among 4 different methods assessing LDL particle characteristics. Clin Chem 2006 52 : 1722 7.
44. Rifai N, Warnick GR, McNamara JR, Belcher JD, Grinstead GF, Frantz ID Jr. Measurement of low-density-lipoprotein cholesterol in serum: a status report. Clin Chem 1992 38 : 150 60.
45. Bayer P, Veinberg F, Couderc R et al. Multicenter evaluation of four homogenous LDL-cholesterol assays. Ann Biol Clin (Paris) 2005 63 : 27 41.
46. Nauck M, Warnick GR, Rifai N. Methods for measurement of LDL-cholesterol: a critical assessment of direct measurement by homogeneous assays versus calculation. Clin Chem 2002 48 : 236 54.
47. Garvey WT, Kwon S, Zheng D et al. Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes 2003 52 : 453 62.
48. Otvos J, Cronwell W, Shalaurova I. LDL particle but not LDL cholesterol are highly elevated in the metabolic syndrome. Results from the Framingham Offspring Study. Circulation 2003 108 : IV 740 (abstract).
49. Ooi EM, Barrett PH, Chan DC, Nestel PJ, Watts GF. Dose-dependent effect of rosuvastatin on apolipoprotein B-100 kinetics in the metabolic syndrome. Atherosclerosis 2008 197 : 139 46.
50. Betteridge DJ, Gibson JM. Effects of rosuvastatin on lipids, lipoproteins and apolipoproteins in the dyslipidaemia of diabetes. Diabet Med 2007 24 : 541 9.
51. Ballantyne CM, Bertolami M, Hernandez Garcia HR et al. vAchieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY) II. Am Heart J 2006 151 : 975. e1-9.
52. Lloret R, Ycas J, Stein M, Haffner S, STARSHIP Study Group. Comparison of rosuvastatin versus atorvastatin in Hispanic-Americans with hypercholesterolemia (from the STARSHIP trial). Am J Cardiol 2006 98 : 768 73.
53. Milionis HJ, Rizos E, Kostapanos M et al. Treating to target patients with primary hyperlipidaemia: comparison of the effects of ATOrvastatin and ROSuvastatin (the ATOROS study). Curr Med Res Opin 2006 22 : 1123 31.
54. Catapano AL, Davidson MH, Ballantyne CM et al. Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients. Curr Med Res Opin 2006 22 : 2041 53.
55. Wolffenbuttel BH, Franken AA, Vincent HH, Dutch Corall Study Group. Cholesterol-lowering effects of rosuvastatin compared with atorvastatin in patients with type 2 diabetes - CORALL study. J Intern Med 2005 257 : 531 9.
56. Lamendola C, Abbasi F, Chu JW et al. Comparative effects of rosuvastatin and gemfibrozil on glucose, insulin, and lipid metabolism in insulin-resistant, nondiabetic patients with combined dyslipidemia. Am J Cardiol 2005 95 : 189 93.
57. Schwartz GG, Bolognese MA, Tremblay BP et al. Efficacy and safety of rosuvastatin and atorvastatin in patients with hypercholesterolemia and a high risk of coronary heart disease: a randomized, controlled trial. Am Heart J 2004 148 : e4.
58. Hunninghake DB, Stein EA, Bays HE et al. Rosuvastatin improves the atherogenic and atheroprotective lipid profiles in patients with hypertriglyceridemia. Coron Artery Dis 2004 15 : 115 23.
59. Jayaram S, Jain MM, Naikawadi AA, Gawde A, Desai A. Comparative evaluation of the efficacy, safety, and tolerability of rosuvastatin 10 mg with atorvastatin 10 mg in adult patients with hypercholesterolaemia: the first Indian study. J Indian Med Assoc 2004 102 : 48 50, 52.
60. Stein EA, Strutt K, Southworth H, Diggle PJ, Miller E, HeFH Study Group. Comparison of rosuvastatin versus atorvastatin in patients with heterozygous familial hypercholesterolemia. Am J Cardiol 2003 92 : 1287 93.
61. Capuzzi DM, Morgan JM, Weiss RJ, Chitra RR, Hutchinson HG, Cressman MD. Beneficial effects of rosuvastatin alone and in combination with extended-release niacin in patients with a combined hyperlipidemia and low high-density lipoprotein cholesterol levels. Am J Cardiol 2003 91 : 1304 10.
62. Davidson M, Ma P, Stein EA et al. Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia. Am J Cardiol 2002 89 : 268 75.
63. Olsson AG, Pears J, McKellar J, Mizan J, Raza A. Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia. Am J Cardiol 2001 88 : 504 8.
64. Alsheikh-Ali AA, Ambrose MS, Kuvin JT et al. The safety of rosuvastatin as used in common clinical practice: a postmarketing analysis. Circulation. 2005 111 : 3051 7.
65. McAfee AT, Ming EE, Seeger JD et al. The comparative safety of rosuvastatin: a retrospective matched cohort study in over 48,000 initiators of statin therapy. Pharmacoepidemiol Drug Saf 2006 15 : 444 53.
66. Zipes DP, Zvaifler NJ, Glassock RJ et al. Rosuvastatin: an independent analysis of risks and benefits. Med Gen Med 2006 8 : 73.
67. Goettsch WG, Heintjes EM, Kastelein JJ et al. Results from a rosuvastatin historical cohort study in more than 45 000 Dutch statin users, a PHARMO study. Pharmacoepidemiol Drug Saf 2006 15 : 435 43.
68. Barter P, Gotto AM, LaRosa JC et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 2007 357 : 1301 10.
69. Asztalos BF, Le Maulf F, Dallal GE et al. Comparison of the effects of high doses of rosuvastatin versus atorvastatin on the subpopulations of high-density lipoproteins. Am J Cardiol 2007 99 : 681 5.